Matinas BioPharma Holdings, Inc. (MTNB)

ASE – Real Time Price. Currency in USD

0.59

-0.05 (-7.84%)

At close: May 12, 2026, 3:59 PM EDT

0.58

-0.01 (-1.42%)

After-hours: May 12, 2026, 7:57 PM EDT

Stock details

Previous close: 0.638049$
Day's range: 0.56 - 0.64$
52-week range: 0.48 - 3.09$
Volume: 16 443
Average volume: 26 741
Beta: 1.86
EPS (TTM): -2.02
PE ratio (TTM): N/A
Forward P/E: N/A
Market cap: 4 087 464
Shares outstanding: 6 406 191
Dividend yield: N/A
Next earnings date: 2026-08-13
Sector: Healthcare
Industry: Biotechnology

About the company

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphoter... read more

CEO: Jerome Jabbour
Country: United States
IPO Date
Employees: 2
Fiscal Year End: January - December
Website: https://www.matinasbiopharm...

Revenue Breakdown

No Data

Revenue breakdown data has not been calculated yet.

News

No Data

There are no news for this stock.

Chart: MTNB

Loading Chart...

Overall Score

2.9 / 1029%

Financial Strength

7.4

Profitability

Effectiveness

Growth

5.5

Forecast

2.1

Valuation

4.1

Dividend

Economic Moat

Octagon View

Strength & Weakness

Company's cash reserves $4.0M significantly exceed its total debt $1.4M, ensuring strong financial flexibility

Total current assets $4.1M exceed Total current liabilities $1.5M, highlighting excellent liquidity

Debt-to-equity ratio (0.3) is well below the industry average (0.3), showcasing prudent financial management

Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns

Financial Strength

NAME	RATIO	INDUSTRY	SCORE
Current ratio	2.79	6.05	10
Quick ratio	2.79	5.63	10
Debt to Equity	0.28	0.30	8.0
Debt to Assets	0.19	1.04	8.0
Interest coverage	N/A	-16.91	1.0
Weighted average score			7.4

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)

Values in USD (B=Billions, M=Millions, K=Thousands)

METRIC	2022	2023	2024	2025	TTM
Total Revenue	3M	1M	N/A	N/A	N/A
Gross Profit	2M	155K	-972K	-456K	-461K
Operating Income	-25M	-24M	-20M	-7M	-7M
Net Income	-21M	-23M	-24M	-11M	-11M
EBITDA	-24M	-23M	-19M	-7M	-6M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAME	RATIO	INDUSTRY	SCORE
Gross margin %	N/A	-11.73	1.0
Operating margin %	N/A	-24.60	1.0
Net margin %	N/A	-172.20	1.0
EBITDA margin %	N/A	-201.27	1.0
Cash flow margin %	N/A	-156.39	1.0
Weighted average score			1.0

Net Margin

Effectiveness

NAME	RATIO	INDUSTRY	SCORE
ROA	-115.62	-57.97	1.0
ROE	-168.27	-63.56	1.0
ROIC	-140.65	-42.57	1.0
ROCE	-21.51	-71.10	1.0
Weighted average score			1.0

Estimated EPS vs Actual EPS

Forecast

NAME	REVENUE GROWTH	EPS GROWTH	SCORE
Current quarter	N/A	N/A	1.0
Next quarter	N/A	N/A	1.0
Current year	N/A	N/A	1.0
Next year	-51.56	50	5.5
Weighted average score			2.1

Analyst Rating

Growth

NAME	REVENUE	NET INCOME	EPS	FCF	SCORE
Q/Q	999	11.07	N/A	N/A	4.8
Y/Y	999	77.33	N/A	N/A	5.5
3y average	277.8	13.28	N/A	10.11	6.5
5y average	2043.71	9.19	2.48	0.41	5.3
Weighted average score					5.5

Revenue Growth Rate vs. Industry

Valuation

NAME	RATIO	INDUSTRY	SCORE
P/E	N/A	-5.25	1.0
PEG (5yr expected)	N/A	0.27	1.0
P/S	34.81	64.66	5.4
P/B	0.89	2.96	8.8
Weighted average score			4.1

DCF Model

DCF Model PeriodN/A

Discount rateN/A

Perpetual growth rateN/A

Revenue 5 year CAGRN/A

FCF 5 year CAGRN/A

Fair valueN/A

Stock price0.638049$

Dividend

NAME	CURRENT	INDUSTRY	SCORE
Dividend yield	0.00	N/A	1.0
Payout ratio	0.00	N/A	1.0
5-year dividend growth rate	N/A	N/A	1.0
Years of dividend increase	N/A	N/A	1.0
Weighted average score			1.0

Fair Value

$1

UndervaluedStock priceOvervalued

$0.638049

Economic Moat

NAME	SCALE	SCORE
Market share	None	1.0
Intangible assets	None	1.0
Switching costs	None	1.0
Network effect	None	1.0
Economies of scale	None	1.0
Weighted average score		1.0

About the company

CEO

Jerome Jabbour

Country

United States

IPO Date

Employees

Fiscal Year End

January - December

Website

https://www.matinasbiopharm...

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Current ratio

2.79

6.05

Quick ratio

2.79

5.63

Debt to Equity

0.28

0.30

8.0

Debt to Assets

0.19

1.04

8.0

Interest coverage

N/A

-16.91

1.0

Weighted average score

7.4

METRIC

2022

2023

2024

2025

TTM

Total Revenue

N/A

Gross Profit

155K

-972K

-456K

-461K

Operating Income

-25M

-24M

-20M

-7M

Net Income

-21M

-23M

-24M

-11M

EBITDA

-24M

-23M

-19M

-7M

-6M

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Gross margin %

N/A

-11.73

1.0

Operating margin %

N/A

-24.60

1.0

Net margin %

N/A

-172.20

1.0

EBITDA margin %

N/A

-201.27

1.0

Cash flow margin %

N/A

-156.39

1.0

Weighted average score

1.0

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

ROA

-115.62

-57.97

1.0

ROE

-168.27

-63.56

1.0

ROIC

-140.65

-42.57

1.0

ROCE

-21.51

-71.10

1.0

Weighted average score

1.0

NAME

REVENUE GROWTH

EPS GROWTH

SCORE

Current quarter

N/A

1.0

Next quarter

N/A

1.0

Current year

N/A

1.0

Next year

-51.56

5.5

Weighted average score

2.1

NAME

REVENUE

NET INCOME

EPS

FCF

SCORE

Q/Q

999

11.07

N/A

4.8

Y/Y

999

77.33

N/A

5.5

3y average

277.8

13.28

N/A

10.11

6.5

5y average

2043.71

9.19

2.48

0.41

5.3

Weighted average score

5.5

NAME

RATIO

INDUSTRY

5Q TREND

SCORE

P/E

N/A

-5.25

1.0

PEG (5yr expected)

N/A

0.27

1.0

P/S

34.81

64.66

5.4

P/B

0.89

2.96

8.8

Weighted average score

4.1

NAME

CURRENT

INDUSTRY

SCORE

Dividend yield

0.00

N/A

1.0

Payout ratio

0.00

N/A

1.0

5-year dividend growth rate

N/A

1.0

Years of dividend increase

N/A

1.0

Weighted average score

1.0

NAME

SCALE

SCORE

Market share

None

1.0

Intangible assets

None

1.0

Switching costs

None

1.0

Network effect

None

1.0

Economies of scale

None

1.0

Weighted average score

1.0

Search stocks

Matinas BioPharma Holdings, Inc. (MTNB)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Matinas BioPharma Holdings, Inc. (MTNB)

Stock details

About the company

Revenue Breakdown

No Data

News

Chart: MTNB

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$1

$0.638049

Economic Moat

Stock details

About the company

Revenue Breakdown

No Data

News

Chart: MTNB

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$1

$0.638049

Economic Moat